Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 17, 2020

SELL
$8.21 - $21.02 $90,310 - $231,220
-11,000 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$7.81 - $18.82 $85,910 - $207,020
11,000 New
11,000 $101,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.